Further, the oncogenic behavior of epidermal growth factor receptor (EGFR), combined to its recently emerged role as important modulator of immune response [27], prompted the evaluation of ipilimumab plus EGFR-tyrosine kinase inhibitor (TKI) erlotinib in a clinical trial in patients with NSCLC [28,29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.